Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + epirubicin + fluorouracil + methotrexate
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A sequential chemotherapy regimen used in the treatment of breast cancer, particularly early-stage and node-positive disease. The regimen typically consists of epirubicin administered first, followed by the standard CMF (cyclophosphamide, methotrexate, and fluorouracil) combination. Clinical trials have shown this sequential approach to be superior to CMF alone for adjuvant treatment of early breast cancer.
- Other names
- epirubicin-CMFE-CMF
02
Targets
TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cyclophosphamide + epirubicin + fluorouracil + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + epirubicin + fluorouracil + methotrexate.